Furthermore, we explored the therapeutic potentials of pharmacological inhibition of GSTP1 by using a GSTP1 inhibitor ezatiostat, an FDA‐approved drug for myelodysplastic syndromes. This evidence concerns the gene GSTP1 and myelodysplastic syndrome.